Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3

Yuliya V. Sherstyuk, Nikita V. Ivanisenko, Alexandra L. Zakharenko, Maria V. Sukhanova, Roman Yu. Peshkov, Ilia V. Eltsov, Mikhail M. Kutuzov, Tatiana A. Kurgina, E. A. Belousova, В. А. Иванисенко, Olga I. Lavrik, Vladimir N. Silnikov, Tatyana V. AbramovaInternational Journal of Molecular Sciences 2019 · DOI

TL;DR

Researchers have designed and synthesized a new class of potential PARP inhibitors by conjugating ADP with morpholino nucleosides. These novel compounds, particularly those with a phosphoramide (P-N) bond and a 5-iodouracil base, show promising inhibitory activity against PARP-1 and PARP-2, suggesting a new avenue for developing selective PARP inhibitors.

What Problem Does This Paper Address?

Poly(ADP-ribose) polymerases (PARPs) are crucial enzymes involved in DNA repair and genomic stability. Inhibiting PARPs is a promising strategy for cancer treatment, especially for BRCA-deficient cancers. While several PARP inhibitors are approved, there's a continuous need for new classes of compounds with improved selectivity, efficacy, and reduced toxicity. Existing PARP inhibitors often mimic nicotinamide, a component of NAD+, and target the nicotinamide binding site. However, the high homology between PARP-1 and PARP-2 catalytic domains makes developing selective inhibitors challenging. This paper aims to address this by exploring novel NAD+ mimetics based on ADP and morpholino nucleosides, investigating their inhibitory potential and seeking to understand their binding mechanisms for improved selectivity.

Methods

The study employed a multi-pronged approach:

  • Synthesis: A series of 16 dinucleoside pyrophosphates were synthesized, combining adenosine diphosphate (ADP) with various morpholino nucleosides. These conjugates were formed via either a phosphoester (P-O) or a phosphoramide (P-N) bond. The synthesis involved established protocols for morpholino nucleoside preparation and coupling reactions.
  • Enzyme Inhibition Assays: The synthesized compounds were screened for their inhibitory activity against the autopoly(ADP-ribosyl)ation of PARP-1 and PARP-2. IC50 values (the concentration required to inhibit enzyme activity by 50%) were determined.
  • Molecular Modeling and Structural Studies: Molecular docking simulations and molecular dynamics were used to predict and analyze the binding modes of the most active compounds within the PARP catalytic domains. This included investigating interactions with key amino acid residues and identifying potential binding sites (nicotinamide or acceptor binding sites).
  • Kinetic Studies: For selected inhibitors, kinetic studies were performed to determine the type of inhibition (e.g., competitive, non-competitive, mixed) using fluorescence anisotropy techniques.

Datasets

Not discussed in the paper. The study relies on experimental data generated from enzyme assays and computational simulations.

Key Insights and Ideas

  • Novel NAD+ Mimetic Design: The creation of ADP-morpholino nucleoside conjugates represents a new structural class of NAD+ analogs for PARP inhibition.
  • Importance of P-N Bond: Introducing a phosphoramide (P-N) bond instead of a phosphoester (P-O) bond significantly enhanced the inhibitory activity of the ADP conjugates. This is hypothesized to stabilize the pyrophosphate group through intramolecular hydrogen bonding.
  • Role of 5-Iodouracil: The 5-iodination of uracil in the morpholino nucleoside moiety led to increased inhibition potency, particularly for PARP-1.
  • Divergent Binding Mechanisms: A key finding is the predicted differential binding of these analogs. Uracil- and thymine-based analogs appear to target the nicotinamide binding site, similar to known inhibitors. However, adenine-based analogs (specifically 10A) were predicted to bind to the acceptor substrate binding site of PARP-2, suggesting a novel mechanism of PARP inhibition.
  • PARP-2 Selectivity of Adenine Analogs: The adenine-containing morpholino nucleoside conjugate (10A) showed a notable selectivity for PARP-2 over PARP-1, potentially due to variations in the acceptor binding site regions between the two enzymes.
  • Morpholino vs. Ribose: Morpholino nucleosides generally exhibited stronger inhibitory activity than their natural ribonucleoside counterparts, suggesting the morpholine ring's favorable interactions within the PARP active site.

Key Results

  • Synthesis: Sixteen dinucleoside pyrophosphates were successfully synthesized with high yields.
  • Inhibition Potency:
    • The most active compound against PARP-1 was 5-iodouracil 2'-aminomethylmorpholino nucleoside (10IU) with an IC50 of 126 ± 6 μM.
  • The most active compound against PARP-2 was adenine 2'-aminomethylmorpholino nucleoside (10A) with an IC50 of 63 ± 10 μM.
  • Compounds with the P-N bond generally showed more pronounced inhibition than those with the P-O bond.
  • PARP-3 Activity: None of the tested compounds showed significant inhibitory activity against PARP-3, either in DNA modification or protein ADP-ribosylation.
  • Type of Inhibition: 10IU and 11IU were identified as competitive inhibitors of PARP-1, while 4IU and 10A exhibited mixed inhibition.

Limitations and Future Work

  • PARP-3 Selectivity: The compounds showed minimal to no activity against PARP-3, indicating a lack of broad-spectrum inhibition. Future work could focus on designing analogs specifically targeting PARP-3.
  • Mechanism of Adenine Analogs: While the adenine-based analogs are predicted to bind to the acceptor site, further experimental validation of this novel mechanism is warranted.
  • Optimization: The study suggests that the P-N bond substitution is a promising strategy for stabilizing the active conformation and enhancing activity. Further optimization of the morpholino nucleoside and ADP components could lead to even more potent and selective inhibitors.
  • In Vivo Studies: The current study is primarily in vitro and computational. Future work should involve in vivo studies to assess the efficacy, pharmacokinetics, and toxicity of these promising compounds.
  • Broader Application: The authors suggest that this work opens new avenues for the rational design of PARP-1/2 specific inhibitors and could inspire the development of other therapeutic agents based on morpholino nucleoside conjugates.

Summary updated

Abstract

We report on the design, synthesis and molecular modeling study of conjugates of adenosine diphosphate (ADP) and morpholino nucleosides as potential selective inhibitors of poly(ADP-ribose)polymerases-1, 2 and 3. Sixteen dinucleoside pyrophosphates containing natural heterocyclic bases as well as 5-haloganeted pyrimidines, and mimicking a main substrate of these enzymes, nicotinamide adenine dinucleotide (NAD+)-molecule, have been synthesized in a high yield. Morpholino nucleosides have been tethered to the β-phosphate of ADP via a phosphoester or phosphoramide bond. Screening of the inhibiting properties of these derivatives on the autopoly(ADP-ribosyl)ation of PARP-1 and PARP-2 has shown that the effect depends upon the type of nucleobase as well as on the linkage between ADP and morpholino nucleoside. The 5-iodination of uracil and the introduction of the P-N bond in NAD+-mimetics have shown to increase inhibition properties. Structural modeling suggested that the P-N bond can stabilize the pyrophosphate group in active conformation due to the formation of an intramolecular hydrogen bond. The most active NAD+ analog against PARP-1 contained 5-iodouracil 2'-aminomethylmorpholino nucleoside with IC50 126 ± 6 μM, while in the case of PARP-2 it was adenine 2'-aminomethylmorpholino nucleoside (IC50 63 ± 10 μM). In silico analysis revealed that thymine and uracil-based NAD+ analogs were recognized as the NAD+-analog that targets the nicotinamide binding site. On the contrary, the adenine 2'-aminomethylmorpholino nucleoside-based NAD+ analogs were predicted to identify as PAR-analogs that target the acceptor binding site of PARP-2, representing a novel molecular mechanism for selective PARP inhibition. This discovery opens a new avenue for the rational design of PARP-1/2 specific inhibitors.
BibTeX
@article{sherstyuk2019design,
  author = {Yuliya V. Sherstyuk and Nikita V. Ivanisenko and Alexandra L. Zakharenko and Maria V. Sukhanova and Roman Yu. Peshkov and Ilia V. Eltsov and Mikhail M. Kutuzov and Tatiana A. Kurgina and E. A. Belousova and В. А. Иванисенко and Olga I. Lavrik and Vladimir N. Silnikov and Tatyana V. Abramova},
  title = {{Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3}},
  journal = {International Journal of Molecular Sciences},
  year = {2019},
  doi = {10.3390/ijms21010214},
}
Figure